Results 61 to 70 of about 3,571 (163)
, 1988 We investigated the effects of phenelzine and tranylcypromine on the release of prostacyclin, thromboxane A2, prostaglandin E2, and prostaglandin E1 from the isolated perfused rat mesenteric vascular bed.
Kenneth D. Jenkins +4 more
core +1 more source
Brainstem levels of transcription factor AP-2 in rat are changed after treatment with phenelzine, but not with citalopram [PDF]
, 2005 BACKGROUND: Before therapeutic effect is obtained after treatment with antidepressant drugs, like serotonin selective reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAO-Is) there is an initial lag-period ...
Cecilia Berggard +5 more
core +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.Abstract INTRODUCTION Central nervous system (CNS) –active polypharmacy, defined as concurrent use of antidepressants, antipsychotics, anti‐seizure medications, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, opioids, or skeletal muscle relaxants for ≥ 31 consecutive days, poses significant risks patients with dementia.
Donovan T. Maust +9 more
wiley +1 more source
BMC Neuroscience, 2010 Background The molecular and biological mechanisms by which many antidepressants function are based on the monoamine depletion hypothesis. However, the entire cascade of mechanisms responsible for the therapeutic effect of antidepressants has not yet ...
Shin Minkyu +8 more
doaj +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.Viloxazine, a serotonin–norepinephrine modulating agent, has been repurposed from an antidepressant to a novel non‐stimulant for ADHD. Its multimodal mechanism and Phase II/III trials demonstrate clinically meaningful symptom reduction with a distinct safety and interaction profile, offering an alternative for patients who cannot tolerate stimulants ...
Ghaith K. Mansour +4 more
wiley +1 more source
Oral Phenelzine Treatment Mitigates Metabolic Disturbances in Mice Fed a High-Fat Diet
, 2019 International audienceNovel mechanisms and health benefits have been recently suggested for the antidepressant drug phenelzine (PHE), known as a nonselective monoamine oxidase inhibitor.
Le-Gonidec, Sophie +7 more
core +1 more source
MedComm, Volume 7, Issue 3, March 2026.Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia +4 more
wiley +1 more source
Archiv der Pharmazie, Volume 359, Issue 2, February 2026.We identified a novel N9‐substituted harmine analog, compound 6, that selectively suppresses leukemic cell growth, triggers DNA damage, and activates apoptosis while sparing healthy fibroblasts. This discovery highlights N9‐modified β‐carbolines as a powerful new class of selective antileukemic agents, bridging natural product chemistry with next ...
Abdul Aziz Timbilla +17 more
wiley +1 more source
Exploration of Novel Small Molecule Phenelzine Analogue LSD1 Inhibitors [PDF]
, 2014 Lysine-specific demethylase 1 (LSD1) is an epigenetic enzyme that oxidatively cleaves methyl groups from monomethyl and dimethyl Lys4 of histone H3 (H3K4me1, H3K4me2) and can contribute to gene silencing.
Prusevich, Polina
core